Get startedLog in
    Picture of Medigene AG logo

    MDG1 — Medigene AG News Story

    0.000.00%
    de flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    All News

    Brief: Medigene Enters Phase I Clinical Development With Its Tcr-T Immunotherapy Mdg1021 In Hematological Cancers

    Picture of Medigene AG logoMedigene AG
    23/06/2020 21:02
    June 23 (Reuters) - Medigene AG  MDG1k.DE :
    * PTA-NEWS: MEDIGENE AG: MEDIGENE ENTERS PHASE I CLINICAL
DEVELOPMENT WITH ITS TCR-T IMMUNOTHERAPY MDG1021 IN
HEMATOLOGICAL CANCERS
    * MEDIGENE AG - RECEIVED APPROVAL FROM DUTCH REGULATORY
AUTHORITY
TO BEGIN FIRST CLINICAL TRIAL OF MDG1021. MDG1021
    * MEDIGENE AG - PHASE I CLINICAL TRIAL IN CANCER PATIENTS
SUFFERING FROM RELAPSE/PERSISTENCE AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION

Source text for Eikon:  ID:nPexSMhb0a 
Further company coverage:  MDG1k.DE 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Medigene AG

    See all news